PURPOSE: Chronic arsenic exposure at levels found in US drinking water has been associated with bladder cancer. While arsenic is a known carcinogen, recent studies suggest that it is useful as a therapeutic agent for leukemia. This study examined the relationship between arsenic exposure and bladder cancer mortality. METHODS: We studied 832 cases of bladder cancer diagnosed in New Hampshire from a population-based case-control study. Individual exposure to arsenic was determined in home drinking water using ICP-MS and in toenail samples by instrumental neutron activation analysis. RESULTS: Among the high arsenic exposure group, found using toenail arsenic level or arsenic consumption, cases experienced a de-escalated survival hazard ratio (HR) [high (> or =75 percent) versus low (<25th percentile) toenail arsenic overall survival HR 0.5 (95% CI 0.4-0.8)], controlled for tumor stage, grade, gender, age and treatment regimen. This association was found largely among invasive tumors, in smokers and was not modified by TP53 status. Bladder cancer cause-specific survival showed a similar trend, but did not reach statistical significance [HR 0.5 (95% CI 0.3-1.1)]. CONCLUSIONS: Arsenic exposure may be related to the survival of patients with bladder cancer.
PURPOSE: Chronic arsenic exposure at levels found in US drinking water has been associated with bladder cancer. While arsenic is a known carcinogen, recent studies suggest that it is useful as a therapeutic agent for leukemia. This study examined the relationship between arsenic exposure and bladder cancer mortality. METHODS: We studied 832 cases of bladder cancer diagnosed in New Hampshire from a population-based case-control study. Individual exposure to arsenic was determined in home drinking water using ICP-MS and in toenail samples by instrumental neutron activation analysis. RESULTS: Among the high arsenic exposure group, found using toenail arsenic level or arsenic consumption, cases experienced a de-escalated survival hazard ratio (HR) [high (> or =75 percent) versus low (<25th percentile) toenail arsenic overall survival HR 0.5 (95% CI 0.4-0.8)], controlled for tumor stage, grade, gender, age and treatment regimen. This association was found largely among invasive tumors, in smokers and was not modified by TP53 status. Bladder cancer cause-specific survival showed a similar trend, but did not reach statistical significance [HR 0.5 (95% CI 0.3-1.1)]. CONCLUSIONS:Arsenic exposure may be related to the survival of patients with bladder cancer.
Authors: M R Karagas; T D Tosteson; J Blum; B Klaue; J E Weiss; V Stannard; V Spate; J S Morris Journal: Am J Epidemiol Date: 2000-07-01 Impact factor: 4.897
Authors: Nicole V Soucy; Michael A Ihnat; Chandrashekhar D Kamat; Linda Hess; Mark J Post; Linda R Klei; Callie Clark; Aaron Barchowsky Journal: Toxicol Sci Date: 2003-09-11 Impact factor: 4.849
Authors: C S Wilhelm-Benartzi; D C Koestler; E A Houseman; B C Christensen; John K Wiencke; A R Schned; M R Karagas; K T Kelsey; C J Marsit Journal: Carcinogenesis Date: 2010-08-28 Impact factor: 4.944
Authors: Nathaniel Holcomb; Mamta Goswami; Sung Gu Han; Tim Scott; John D'Orazio; David K Orren; C Gary Gairola; Isabel Mellon Journal: DNA Repair (Amst) Date: 2017-02-16
Authors: Jennifer L Beebe-Dimmer; Priyanka T Iyer; Jerome O Nriagu; Greg R Keele; Shilpin Mehta; Jaymie R Meliker; Ethan M Lange; Ann G Schwartz; Kimberly A Zuhlke; David Schottenfeld; Kathleen A Cooney Journal: Environ Health Date: 2012-06-29 Impact factor: 5.984
Authors: Irina Mordukhovich; Robert O Wright; Howard Hu; Chitra Amarasiriwardena; Andrea Baccarelli; Augusto Litonjua; David Sparrow; Pantel Vokonas; Joel Schwartz Journal: Environ Health Perspect Date: 2011-08-30 Impact factor: 9.031
Authors: Antonio J Signes-Pastor; Enrique Gutiérrez-González; Miguel García-Villarino; Francisco D Rodríguez-Cabrera; Jorge J López-Moreno; Elena Varea-Jiménez; Roberto Pastor-Barriuso; Marina Pollán; Ana Navas-Acien; Beatriz Pérez-Gómez; Margaret R Karagas Journal: Environ Res Date: 2020-10-16 Impact factor: 6.498